Second-Generation Phage Lambda Platform Employing SARS-CoV-2 Fusion Proteins as a Vaccine Candidate

The recent SARS-CoV-2 (COVID-19) pandemic exemplifies how newly emerging and reemerging viruses can quickly overwhelm and cripple global infrastructures. Coupled with synergistic factors such as increasing population densities, the constant and massive mobility of people across geographical areas an...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2024-10, Vol.12 (11), p.1201
Main Authors: Catala, Alexis, Davenport, Bennett J, Morrison, Thomas E, Catalano, Carlos E
Format: Article
Language:English
Subjects:
Antigenicity
Bacteriophages
Chromatography
COVID-19
COVID-19 vaccines
E coli
Glycerol
Health aspects
Immunization
Infectious diseases
nanomedicine
Pandemics
phage-like particles
Phages
Population density
Population growth
Proteins
Public health
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Sodium
vaccine development
Vaccines
Viral diseases
viral nanoparticles
Viruses
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The recent SARS-CoV-2 (COVID-19) pandemic exemplifies how newly emerging and reemerging viruses can quickly overwhelm and cripple global infrastructures. Coupled with synergistic factors such as increasing population densities, the constant and massive mobility of people across geographical areas and substantial changes to ecosystems worldwide, these pathogens pose serious health concerns on a global scale. Vaccines form an indispensable defense, serving to control and mitigate the impact of devastating outbreaks and pandemics. Towards these efforts, we developed a tunable vaccine platform that can be engineered to simultaneously display multiple viral antigens. Here, we describe a second-generation version wherein chimeric proteins derived from SARS-CoV-2 and bacteriophage lambda are engineered and used to decorate phage-like particles with defined surface densities and retention of antigenicity. This streamlines the engineering of particle decoration, thus improving the overall manufacturing potential of the system. In a prime-boost regimen, mice immunized with particles containing as little as 42 copies of the chimeric protein on their surface develop potent neutralizing antibody responses, and immunization protects mice against virulent SARS-CoV-2 challenge. The platform is highly versatile, making it a promising strategy to rapidly develop vaccines against a potentially broad range of infectious diseases.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines12111201